Prolocor

Prolocor

Biotechnology, 60 St Martin South Ln, Philadelphia, Pennsylvania, United States, 1-10 Employees

prolocor.com

  • LinkedIn

Who is PROLOCOR

There are 50 million people living with chronic coronary artery disease in the U.S., Europe, and Japan. Of these, over 2 million suffer from acute coronary syndrome every year. In each ca...

Read More

map
  • 60 St Martin South Ln, Philadelphia, Pennsylvania, United States Headquarters: 60 St Martin South Ln, Philadelphia, Pennsylvania, United States
  • 2020 Date Founded: 2020
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $25 Million to $50 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from PROLOCOR

Prolocor Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Prolocor

Answer: Prolocor's headquarters are located at 60 St Martin South Ln, Philadelphia, Pennsylvania, United States

Answer: Prolocor's official website is https://prolocor.com

Answer: Prolocor's revenue is $25 Million to $50 Million

Answer: Prolocor's SIC: 8731

Answer: Prolocor's NAICS: 541714

Answer: Prolocor has 1-10 employees

Answer: Prolocor is in Biotechnology

Answer: Prolocor contact info: Phone number: Website: https://prolocor.com

Answer: There are 50 million people living with chronic coronary artery disease in the U.S., Europe, and Japan. Of these, over 2 million suffer from acute coronary syndrome every year. In each case, the doctor and patient must decide whether to use more powerful therapy to prevent thrombosis increasing the risk of bleeding or less intensive therapy reducing bleeding risk at the expense of more thrombotic events such as heart attack, stroke, and cardiovascular death. Prolocors precision tool will guide treatment decisions, effectively matching the intensity of therapy with the risk of events. Founded by a team that deeply understands thrombosis and cardiovascular disease, Prolocor is building its strategy around platelet FcRIIa and embarking on a journey to commercialize an innovative precision diagnostic test that quantifies FcRIIa on the surface of platelets.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access